{
    "id": 32886,
    "fullName": "PDGFRB C843G",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PDGFRB C843G lies within the protein kinase domain of the Pdgfrb protein (UniProt.org). C843G has been associated with secondary drug resistance in the context of AGGF1-PDGFRB (PMID: 29434033), but has not been biochemically characterized and therefore, its effect on Pdgfrb protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5159,
        "geneSymbol": "PDGFRB",
        "terms": [
            "PDGFRB",
            "CD140B",
            "IBGC4",
            "IMF1",
            "JTK12",
            "KOGS",
            "PDGFR",
            "PDGFR-1",
            "PDGFR1",
            "PENTT"
        ]
    },
    "variant": "C843G",
    "createDate": "03/25/2020",
    "updateDate": "03/25/2020",
    "referenceTranscriptCoordinates": {
        "id": 188642,
        "transcript": "NM_002609",
        "gDna": "chr5:g.150120947A>C",
        "cDna": "c.2527T>G",
        "protein": "p.C843G",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21154,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient harboring AGGF1-PDGFRB who initially responded to treatment with Gleevec (imatinib) experienced relapse and subsequent testing revealed PDGFRB C843G (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80144,
                "name": "childhood acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing AGGF1-PDGFRB and PDGFRB C843G were sensitive to treatment with CHZ868 in culture, demonstrating reduced cell viability (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21147,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Gleevec (imatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Tasigna (nilotinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21150,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Iclusig (ponatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21148,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells co-expressing AGGF1-PDGFRB and PDGFRB C843G demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35564,
                "profileName": "AGGF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21157,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Tasigna (nilotinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21158,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Iclusig (ponatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21156,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB C843G were sensitive to treatment with CHZ868 in culture, demonstrating reduced cell viability (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21155,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EBF1-PDGFRB and PDGFRB D843G were resistant to treatment with Gleevec (imatinib) in culture (PMID: 29434033).",
            "molecularProfile": {
                "id": 35565,
                "profileName": "EBF1 - PDGFRB PDGFRB C843G"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18429,
                    "pubMedId": 29434033,
                    "title": "PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29434033"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35562,
            "profileName": "PDGFRB C843G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35564,
            "profileName": "AGGF1 - PDGFRB PDGFRB C843G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35565,
            "profileName": "EBF1 - PDGFRB PDGFRB C843G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188641,
            "transcript": "XM_011537659",
            "gDna": "chr5:g.150120947A>C",
            "cDna": "c.2527T>G",
            "protein": "p.C843G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188642,
            "transcript": "NM_002609",
            "gDna": "chr5:g.150120947A>C",
            "cDna": "c.2527T>G",
            "protein": "p.C843G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188643,
            "transcript": "XM_011537658",
            "gDna": "chr5:g.150120947A>C",
            "cDna": "c.2527T>G",
            "protein": "p.C843G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}